Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety in the Latin American (LA) subpopulation of global Phase 3 and long-term extension (LTE) studies. Data from LA patients with RA and inadequate response to disease...

Full description

Bibliographic Details

Published in:	Reumatología clinica (Barcelona) Vol. 13; no. 4; pp. 201 - 209
Main Authors:	Radominski, Sebastião Cezar, Cardiel, Mario Humberto, Citera, Gustavo, Goecke, Annelise, Jaller, Juan Jose, Lomonte, Andrea Barranjard Vannucci, Miranda, Pedro, Velez, Patricia, Xibillé, Daniel, Kwok, Kenneth, Rojo, Ricardo, García, Erika Gabriela
Format:	Journal Article
Language:	English
Published:	Elsevier España, S.L.U 01-07-2017
Subjects:	Artritis reumatoide Janus kinase Kinasas Janus Latin America Latinoamérica Rheumatoid arthritis Tofacitinib Latinoamérica Artritis reumatoide Tofacitinib Rheumatoid arthritis Janus kinase Kinasas Janus Latin America
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!